Dynamic Ocular Hydrogel Depot for Sustained Intravitreal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ocular therapies for conditions like macular degeneration and diabetic macular edema face challenges with patient compliance due to the need for frequent injections, and existing long-acting delivery technologies have limitations such as burst release, complex manufacturing, and potential immune responses, necessitating the development of novel, injectable systems for controlled and sustained delivery of ocular therapeutics.
Innovation Solution
The use of dynamic hydrogels composed of polymer nanoparticles and hydrophobically modified cellulose derivatives, which exhibit shear-thinning and self-healing properties, allowing for straightforward administration and sustained release of ocular therapeutics, such as prostaglandin analogs, through non-covalent interactions, providing a depot that maintains therapeutic levels for up to two months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional intravitreal injection is used for ocular therapy, then therapeutic effect is achieved, but patient compliance deteriorates due to frequent injections
Solution Approach 1:
The patent employs dynamic hydrogels that exhibit shear-thinning behavior, allowing the formulation to transition from a liquid state during injection to a gel state in the vitreous humor. This dynamic property enables the system to provide sustained therapeutic delivery while maintaining ease of administration through standard intravitreal injection procedures
Solution Approach 2:
The hydrogel depot provides continuous and sustained release of ocular therapeutics over extended periods (up to two months), eliminating the need for frequent repeated injections. The continuous action is achieved through controlled degradation and release mechanisms within the hydrogel matrix
2Duration of action of stationary object
If existing long-acting delivery technologies are used, then injection frequency is reduced, but burst release occurs compromising safety
Solution Approach 1:
The patent controls the release parameters of the therapeutic agent by adjusting hydrogel composition, crosslinking density, and degradation kinetics. These parameter modifications ensure sustained release without burst release, maintaining safe and consistent therapeutic levels throughout the delivery period
Solution Approach 2:
The hydrogel acts as an intermediary carrier between the therapeutic agent and the target tissue. It controls the release kinetics through its matrix structure, preventing direct bolus release while maintaining sustained delivery over the desired duration
3Duration of action of stationary object
If biodegradable implants are used for sustained delivery, then delivery duration is extended, but immune response may occur
Solution Approach 1:
The patent modifies the biodegradability parameters of the hydrogel through selection of specific polymers and crosslinking densities. This allows tuning of the degradation rate to match therapeutic delivery requirements while minimizing immune recognition and response to the delivery system
Solution Approach 2:
The hydrogel is designed as a temporary, biodegradable delivery platform that performs its function and then naturally degrades. This approach avoids permanent implants and their associated chronic immune responses, using a self-resolving system that eliminates itself after delivering the therapeutic payload
4Duration of action of stationary object
If conventional hydrogel formulations are used, then depot formation is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent separates the formulation into distinct functional components: hydrogel matrix, crosslinking agents, and therapeutic payload. This segmentation allows independent optimization and simplified manufacturing of each component, reducing overall process complexity while maintaining effective depot formation
Solution Approach 2:
The patent employs physical crosslinking mechanisms that can be triggered under simple conditions (e.g., temperature, pH, or ionic strength changes). This approach avoids complex chemical synthesis or multi-step processing, enabling straightforward manufacturing while achieving the desired depot characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dynamic hydrogels offer improved patient convenience, consistent drug release, reduced side effects, and biocompatibility, addressing the shortcomings of conventional hydrogel-based depot technologies by enabling facile formulation, injectability, and prolonged therapeutic delivery.
Implementation Method 1
The dynamic hydrogels exhibit shear-thinning and self-healing properties
Implementation Method 2
The dynamic hydrogels exhibit shear-thinning and self-healing properties
Implementation Method 3
composed of polymer nanoparticles and hydrophobically modified cellulose derivatives... through non-covalent interactions
Implementation Method 4
hydrophobically modified cellulose derivatives... non-covalent interactions
Data Source
AI summary
Compositions for treating ocular disease are disclosed herein. In some embodiments, the composition comprises a dynamic hydrogel comprising a polymer and a plurality of nanoparticles, wherein the polymer is non-covalently crosslinked with the plurality of nanoparticles. The dynamic hydrogel can also comprise an ocular therapeutic encapsulated by the dynamic hydrogel.